Lawsuit Alleges Man’s Bladder Cancer Caused by Actos

actos-caused-bladder-cancerA Pennsylvania man alleges that he developed bladder cancer as a result of taking the diabetes drug Actos (pioglitazone).

According to the lawsuit filed earlier this month, the man began taking Actos in August 2009 and developed bladder cancer in March 2011. The lawsuit alleges that Takeda Pharmaceuticals and the other defendants named in the action knew Actos could cause bladder cancer, but did not warn the plaintiff or the public. The suit further claims that the defendants misrepresented and omitted information to conceal the risks of taking Actos.

Parker Waichman LLP filed the lawsuit on February 5th in the U.S. District Court for the Western District of Louisiana, Lafayette Division (Case No. 6:13-cv-0267). This is one of many cases pending in the Actos multidistrict litigation (MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiff’s Steering Committee in the litigation.

The plaintiff is suing for permanent injuries, severe mental and physical pain, emotional distress, and economic loss caused by medical expenses and new living expenses related to necessary changes in his lifestyle.

The U.S. Food and Drug Administration (FDA) says that data from an ongoing 10-year study being conducted by Kaiser Permanente reveals that using Actos for more than one year may significantly increase the risk of developing bladder cancer. In 2011, the agency updated the medication’s warning label to include this risk. The British Medical Journal (BMJ) published a study in May 2012 showing that patients who took Actos for two years were twice as likely to get bladder cancer, and a study in the Canadian Medical Association Journal reported a 22 percent increase in the risk of developing bladder cancer for Actos users. Research suggests that there are several safer alternatives to Actos.

This entry was posted in Actos, Pharmaceuticals. Bookmark the permalink.

© 2005-2019 Parker Waichman LLP ®. All Rights Reserved.